» Articles » PMID: 31453130

Effect of L. Seeds in Letrozole Induced Polycystic Ovarian Syndrome

Overview
Date 2019 Aug 28
PMID 31453130
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical management of PCOS is multifaceted but often unsatisfactory. The aim of the current study is to evaluate the effect of L. in the letrozole-induced polycystic ovarian syndrome. Female Sprague-Dawley rats were divided into six groups, each containing 6 animals. Group I (Control) daily received 1% carboxymethylcellulose (CMC) suspension as a vehicle control. Letrozole (1 mg/kg) was administered per orally (p.o) for a period of 21 days for the induction of PCOS in Group II to VI. PCOS induced animals were treated with aqueous (Group III - 200 mg/kg and IV- 400 mg/kg) and hydroalcoholic extract (Group V- 200 mg/kg and VI- 400 mg/kg) of up to 66 days using 0.5% w/v CMC as the vehicle. Body weight and estrous cycle phase were measured every day. Blood samples were collected on 0, 21 and 66 days for the measurement of fasting blood glucose, lipid profile, LH, FSH and hormonal level. Oral glucose tolerance test was performed to study insulin resistance effect. Toxicity markers; SGOT, SGPT, and creatinine also measured at the end of the study. The administration of Letrozole led to an abnormality in serum sex steroid profile, lipid profile, glucose and estrous cycle. It was able to successfully exert its protective effect by restoring parameters to the normal level and disappearance of cysts in ovaries. This can be attributed to phyto-components present in the extract. The aqueous and hydro-alcoholic extracts of seeds of showed significant amelioration of Letrozole induced PCOS.

Citing Articles

Mitigation of letrozole induced polycystic ovarian syndrome associated inflammatory response and endocrinal dysfunction by Vitex negundo seeds.

Kar T, Sil S, Ghosh A, Barman A, Chattopadhyay S J Ovarian Res. 2024; 17(1):76.

PMID: 38589892 PMC: 11000293. DOI: 10.1186/s13048-024-01378-4.


Exploring the Therapeutic Potential of Natural Products in Polycystic Ovarian Syndrome (PCOS): A Mini-Review of Lipid Profile, Blood Glucose, and Ovarian Histological Improvements.

Wahid S, Che Ramli M, Fazleen N, Naim R, Mokhtar M Life (Basel). 2024; 14(1).

PMID: 38276279 PMC: 10817691. DOI: 10.3390/life14010150.


Therapeutic Effect of Extracts on Letrozole-Induced Polycystic Ovarian Syndrome and its Complications in Murine Model.

Rani R, Sharma A, Chitme H Clin Med Insights Endocrinol Diabetes. 2023; 16:11795514231203864.

PMID: 37901891 PMC: 10612436. DOI: 10.1177/11795514231203864.


Regulation of Insulin Resistance, Lipid Profile and Glucose Metabolism Associated with Polycystic Ovary Syndrome by .

Rani R, Chitme H, Kukreti N, Pant P, Abdel-Wahab B, Khateeb M Nutrients. 2023; 15(10).

PMID: 37242122 PMC: 10221073. DOI: 10.3390/nu15102238.


Suppression of neurotransmission on gonadotropin-releasing hormone neurons in letrozole-induced polycystic ovary syndrome: A mouse model.

Bhattarai P, Rijal S, Bhattarai J, Cho D, Han S Front Endocrinol (Lausanne). 2023; 13:1059255.

PMID: 36699037 PMC: 9868609. DOI: 10.3389/fendo.2022.1059255.


References
1.
Legro R, Kunselman A, Dunaif A . Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2002; 111(8):607-13. DOI: 10.1016/s0002-9343(01)00948-2. View

2.
Franks S . Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab. 2002; 16(2):263-72. DOI: 10.1053/beem.2002.0203. View

3.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R . Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002; 26(7):883-96. DOI: 10.1038/sj.ijo.0801994. View

4.
Dharmasiri M, Jayakody J, Galhena G, Liyanage S, Ratnasooriya W . Anti-inflammatory and analgesic activities of mature fresh leaves of Vitex negundo. J Ethnopharmacol. 2003; 87(2-3):199-206. DOI: 10.1016/s0378-8741(03)00159-4. View

5.
Kafali H, Iriadam M, Ozardali I, Demir N . Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004; 35(2):103-8. DOI: 10.1016/j.arcmed.2003.10.005. View